RARE vs BIIB Comparison: AI Score, Valuation, Performance and Upside
Compare Ultragenyx and Biogen by rare disease pipeline breadth, commercialization risk, platform technology (gene vs antibody), pathway to profitability, and which biotech offers better near-term catalysts.
Use this Ultragenyx vs Biogen comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
RARE and BIIB are closely matched — they split the tracked metrics evenly. BIIB has delivered stronger 1-year price return (+52.49% vs -1.47%), though RARE has the better forward P/E setup (8.61x vs 12.45x for BIIB). Analyst consensus implies meaningfully more upside for RARE (+98.40%) than for BIIB (+9.86%).
| Metric | RARE | BIIB |
|---|---|---|
| AI score | 25.3 | 28.9 |
| AI rank | #2840 | #2383 |
| Latest close | $26.90 | $202.19 |
| 1M return | -7.59% | +1.30% |
| 6M return | +14.96% | +17.83% |
| 1Y return | -1.47% | +52.49% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RARE | BIIB |
|---|---|---|
| 1Y ago | $9.85K (-1.5%) started 2025-07-24 | $15.37K (+53.7%) started 2025-07-25 |
| 5Y ago | $3.39K (-66.1%) started 2021-07-26 | $6.09K (-39.1%) started 2021-07-26 |
| 10Y ago | $4.96K (-50.4%) started 2016-07-25 | $7.04K (-29.6%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | RARE | BIIB |
|---|---|---|
| Market cap | $2.65B | $30.41B |
| Trailing P/E | N/A | 22.17 |
| Forward P/E | 8.61 | 12.45 |
| Price/Sales | 3.95 | 1.99 |
| EV/Revenue | 5.13 | 3.29 |
| Analyst target | $53.37 | $226.29 |
| Target upside | +98.40% | +9.86% |
| Metric | RARE | BIIB |
|---|---|---|
| Revenue growth | -2.20% | 1.90% |
| Earnings growth | N/A | 31.10% |
| EPS growth | N/A | +31.10% |
| FCF margin | -32.70% | +19.43% |
| Operating margin | N/A | 22.90% |
| Profit margin | -90.90% | 13.80% |
| ROIC proxy | N/A | 7.70% |
| Return on equity | N/A | 7.70% |
| Dividend yield | 0.00% | N/A |
| Beta | 0.31 | 0.16 |
| Debt/equity | N/A | 35.18 |
| Current ratio | 2.02 | 3.06 |
| Quick ratio | 1.65 | 2.02 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RARE | BIIB |
|---|---|---|---|
| 1Y | Growth | -1.47% | +53.73% |
| CAGR | -1.47% | +53.93% | |
| Sharpe ratio | 0.30 | 1.27 | |
| Max drawdown | 49.37% | 14.34% | |
| Max daily drop | 42.32% | 8.17% | |
| Max wkly drop | 41.13% | 12.37% | |
| 5Y | Growth | -66.10% | -39.09% |
| CAGR | -19.48% | -9.45% | |
| Sharpe ratio | -0.19 | -0.25 | |
| Max drawdown | 81.93% | 67.59% | |
| Max daily drop | 42.32% | 8.17% | |
| Max wkly drop | 41.13% | 13.62% | |
| 10Y | Growth | -50.39% | -29.64% |
| CAGR | -6.77% | -3.45% | |
| Sharpe ratio | 0.08 | 0.00 | |
| Max drawdown | 89.57% | 72.66% | |
| Max daily drop | 42.32% | 29.23% | |
| Max wkly drop | 41.13% | 34.30% |
| Category | RARE | BIIB |
|---|---|---|
| Company | RARE | BIIB |
| Sector | N/A | Healthcare |
| Industry | N/A | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.